Eikon Therapeutics appoints Ching-Pin Chang as EV P and CSO
Eikon Therapeutics announced the appointment of Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer.
MILLBRAE, Calif., Sept.
03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc.
NASDAQ:EIKN (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin (“CP”) Chang, M.D…